Cargando…

The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs

BACKGROUND: Asthma is a chronic respiratory disease in which the nervous system plays a central role. Sensory nerve activation, amongst others via Transient Receptor Potential Ankyrin 1 (TRPA1) channels, contributes to asthma characteristics including cough, bronchoconstriction, mucus secretion, air...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Berg, Mariska P. M., Nijboer-Brinksma, Susan, Bos, I. Sophie T., van den Berge, Maarten, Lamb, David, van Faassen, Martijn, Kema, Ido P., Gosens, Reinoud, Kistemaker, Loes E. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871391/
https://www.ncbi.nlm.nih.gov/pubmed/33557843
http://dx.doi.org/10.1186/s12931-021-01638-7
_version_ 1783648999300923392
author van den Berg, Mariska P. M.
Nijboer-Brinksma, Susan
Bos, I. Sophie T.
van den Berge, Maarten
Lamb, David
van Faassen, Martijn
Kema, Ido P.
Gosens, Reinoud
Kistemaker, Loes E. M.
author_facet van den Berg, Mariska P. M.
Nijboer-Brinksma, Susan
Bos, I. Sophie T.
van den Berge, Maarten
Lamb, David
van Faassen, Martijn
Kema, Ido P.
Gosens, Reinoud
Kistemaker, Loes E. M.
author_sort van den Berg, Mariska P. M.
collection PubMed
description BACKGROUND: Asthma is a chronic respiratory disease in which the nervous system plays a central role. Sensory nerve activation, amongst others via Transient Receptor Potential Ankyrin 1 (TRPA1) channels, contributes to asthma characteristics including cough, bronchoconstriction, mucus secretion, airway hyperresponsiveness (AHR) and inflammation. In the current study, we evaluated the efficacy of the novel TRPA1 antagonist BI01305834 against AHR and inflammation in guinea-pig models of asthma. METHODS: First, a pilot study was performed in a guinea-pig model of allergic asthma to find the optimal dose of BI01305834. Next, the effect of BI01305834 on (1) AHR to inhaled histamine after the early and late asthmatic reaction (EAR and LAR), (2) magnitude of EAR and LAR and (3) airway inflammation was assessed. Precision-cut lung slices and trachea strips were used to investigate the bronchoprotective and bronchodilating-effect of BI01305834. Statistical evaluation of differences of in vivo data was performed using a Mann–Whitney U test or One-way nonparametric Kruskal–Wallis ANOVA, for ex vivo data One- or Two-way ANOVA was used, all with Dunnett’s post-hoc test where appropriate. RESULTS: A dose of 1 mg/kg BI01305834 was selected based on AHR and exposure data in blood samples from the pilot study. In the subsequent study, 1 mg/kg BI01305834 inhibited AHR after the EAR, and the development of EAR and LAR elicited by ovalbumin in ovalbumin-sensitized guinea pigs. BI01305834 did not inhibit allergen-induced total and differential cells in the lavage fluid and interleukin-13 gene expression in lung homogenates. Furthermore, BI01305834 was able to inhibit allergen and histamine-induced airway narrowing in guinea-pig lung slices, without affecting histamine release, and reverse allergen-induced bronchoconstriction in guinea-pig trachea strips. CONCLUSIONS: TRPA1 inhibition protects against AHR and the EAR and LAR in vivo and allergen and histamine-induced airway narrowing ex vivo, and reverses allergen-induced bronchoconstriction independently of inflammation. This effect was partially dependent upon histamine, suggesting a neuronal and possible non-neuronal role for TRPA1 in allergen-induced bronchoconstriction.
format Online
Article
Text
id pubmed-7871391
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78713912021-02-09 The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs van den Berg, Mariska P. M. Nijboer-Brinksma, Susan Bos, I. Sophie T. van den Berge, Maarten Lamb, David van Faassen, Martijn Kema, Ido P. Gosens, Reinoud Kistemaker, Loes E. M. Respir Res Research BACKGROUND: Asthma is a chronic respiratory disease in which the nervous system plays a central role. Sensory nerve activation, amongst others via Transient Receptor Potential Ankyrin 1 (TRPA1) channels, contributes to asthma characteristics including cough, bronchoconstriction, mucus secretion, airway hyperresponsiveness (AHR) and inflammation. In the current study, we evaluated the efficacy of the novel TRPA1 antagonist BI01305834 against AHR and inflammation in guinea-pig models of asthma. METHODS: First, a pilot study was performed in a guinea-pig model of allergic asthma to find the optimal dose of BI01305834. Next, the effect of BI01305834 on (1) AHR to inhaled histamine after the early and late asthmatic reaction (EAR and LAR), (2) magnitude of EAR and LAR and (3) airway inflammation was assessed. Precision-cut lung slices and trachea strips were used to investigate the bronchoprotective and bronchodilating-effect of BI01305834. Statistical evaluation of differences of in vivo data was performed using a Mann–Whitney U test or One-way nonparametric Kruskal–Wallis ANOVA, for ex vivo data One- or Two-way ANOVA was used, all with Dunnett’s post-hoc test where appropriate. RESULTS: A dose of 1 mg/kg BI01305834 was selected based on AHR and exposure data in blood samples from the pilot study. In the subsequent study, 1 mg/kg BI01305834 inhibited AHR after the EAR, and the development of EAR and LAR elicited by ovalbumin in ovalbumin-sensitized guinea pigs. BI01305834 did not inhibit allergen-induced total and differential cells in the lavage fluid and interleukin-13 gene expression in lung homogenates. Furthermore, BI01305834 was able to inhibit allergen and histamine-induced airway narrowing in guinea-pig lung slices, without affecting histamine release, and reverse allergen-induced bronchoconstriction in guinea-pig trachea strips. CONCLUSIONS: TRPA1 inhibition protects against AHR and the EAR and LAR in vivo and allergen and histamine-induced airway narrowing ex vivo, and reverses allergen-induced bronchoconstriction independently of inflammation. This effect was partially dependent upon histamine, suggesting a neuronal and possible non-neuronal role for TRPA1 in allergen-induced bronchoconstriction. BioMed Central 2021-02-08 2021 /pmc/articles/PMC7871391/ /pubmed/33557843 http://dx.doi.org/10.1186/s12931-021-01638-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
van den Berg, Mariska P. M.
Nijboer-Brinksma, Susan
Bos, I. Sophie T.
van den Berge, Maarten
Lamb, David
van Faassen, Martijn
Kema, Ido P.
Gosens, Reinoud
Kistemaker, Loes E. M.
The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
title The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
title_full The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
title_fullStr The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
title_full_unstemmed The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
title_short The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
title_sort novel trpa1 antagonist bi01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871391/
https://www.ncbi.nlm.nih.gov/pubmed/33557843
http://dx.doi.org/10.1186/s12931-021-01638-7
work_keys_str_mv AT vandenbergmariskapm thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT nijboerbrinksmasusan thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT bosisophiet thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT vandenbergemaarten thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT lambdavid thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT vanfaassenmartijn thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT kemaidop thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT gosensreinoud thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT kistemakerloesem thenoveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT vandenbergmariskapm noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT nijboerbrinksmasusan noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT bosisophiet noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT vandenbergemaarten noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT lambdavid noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT vanfaassenmartijn noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT kemaidop noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT gosensreinoud noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs
AT kistemakerloesem noveltrpa1antagonistbi01305834inhibitsovalbumininducedbronchoconstrictioninguineapigs